Company profile

ACOR stock data

(
)

Calendar

7 Aug 19
17 Sep 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 50.05M 44.14M 69.15M 142.81M
Net income -27.49M -47.61M 9.6M -13.91M
Diluted EPS -0.58 -1 0.2 -0.29
Net profit margin -54.91% -108% 13.88% -9.74%
Operating income -23.39M -43.38M -49.3M 28.3M
Net change in cash -49.45M -96.47M -27.45M 77.67M
Cash on hand 147.65M 197.09M 293.56M 321.01M
Cost of revenue 9.4M 8.8M 21.48M 25.39M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 471.43M 588.29M 519.6M 492.66M
Net income 33.68M -223.36M -34.62M 11.06M
Diluted EPS 0.71 -4.86 -0.76 0.25
Net profit margin 7.14% -37.97% -6.66% 2.24%
Operating income 38.49M -232.81M -35.98M 33.99M
Net change in cash -13.5M 148.53M 5.33M -28.97M
Cash on hand 293.56M 307.07M 158.54M 153.2M
Cost of revenue 99.31M 135.08M 107.48M 92.3M

Financial data from company earnings reports

Financial report summary

?
Management Discussion
  • We recognize product sales of Inbrija following receipt of product by companies in our distribution network, which primarily includes specialty pharmacy providers and ASD Specialty Healthcare, Inc. We recognized net revenue from the sale of Inbrija of $3.0 million for the three-month period ended June 30, 2019.
  • We recognize product sales of Ampyra following receipt of product by companies in our distribution network, which primarily includes specialty pharmacy providers and ASD Specialty Healthcare, Inc. We recognized net revenue from the sale of Ampyra of $44.2 million and $150.3 million for the three-month periods ended June 30, 2019 and 2018, respectively, a decrease of $106.1 million, or 71%. The net revenue decrease comprised decreased net volume of $122.6 million partially offset by discount and allowance adjustments of $16.5 million.
  • Discounts and allowances which are included as an offset in net revenue consist of allowances for customer credits, including estimated chargebacks, rebates, returns and discounts. Discounts and allowances are recorded following shipment of our products Inbrija and Ampyra to our customers. Adjustments are recorded for estimated chargebacks, rebates, and discounts. Discounts and allowances also consist of discounts provided to Medicare beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”). Payment of coverage gap discounts is required under the Affordable Care Act, the health care reform legislation enacted in 2010. Discounts and allowances may increase as a percentage of sales as we enter into managed care contracts in the future.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AbbieVie, attempt, Aubagio, Avonex, Bayer, behalf, Betaseron, circumstance, Copaxone, CRL, duly, EC, exceeded, exhibit, Extavia, formatted, frequency, Genzyme, Gilenya, Glatopa, Idec, Impel, incorporate, Inline, Instance, intranasally, IRS, Lemtrada, Linkbase, lived, Merck, Neuropharma, Page, physical, Plegridy, procedure, pursuing, quantitative, Rebif, recommending, recoverability, redacted, regularly, restart, Rituxan, Roche, Sandoz, Sanofi, Schema, Secretary, Serono, sudden, symptom, Taxonomy, Tecfidera, thereunto, Tysabri, undersigned, undiscounted, XBRL, Zinbryta
Removed: American, bioavailability, bronchoconstriction, chest, commonly, description, discomfort, evidence, faster, feeling, headache, healthy, hot, ingredient, injection, large, median, nasal, partner, pharmacokinetic, poor, prescribed, profile, reversible, scientific, Society, spray, subcutaneously, tablet, Tmax